Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

Summary

The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.

Timeline

Start

2017-03-21

Primary completion

2027-07-31

Completion

2027-12-31

Drugs

Indications